IA

Initizar Ahmed Khan

Active Director Director DIN 10057157
DIN 10057157 First appointment Feb 2023
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Feb 2023
Shareholding value •••• Premium profile

About Initizar Ahmed Khan

Data last updated:

Initizar Ahmed Khan is a Director at Dbact Pharma Private Limited (since 2023). Dbact Pharma Private Limited reported revenue of ₹21.1 Lakh (FY 2024).

DIN 10057157
Primary Designation Director
First Appointment 27 Feb 2023
Oldest Company Age 3 yrs
Largest company Dbact Pharma Private Limited · ₹21.1 Lakh (FY 2024)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Dbact Pharma Private Limited U46497DL2023PTC410598
Director27 Feb 20232023₹21.1 Lakh (FY 2024)Active

Board colleagues of Initizar Ahmed Khan

NameDINCompanyDesignation
Aftab Ahmad Khan10057158Dbact Pharma Private LimitedDirector

Directorship timeline

Open interactive timeline →
Dbact Pharma Private Limited
Premium access

Shareholding and investment profile for Initizar Ahmed Khan

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Initizar Ahmed Khan

Initizar Ahmed Khan currently holds 1 directorship: Dbact Pharma Private Limited (Director, since 27 Feb 2023, revenue ₹21.1 Lakh (FY 2024)).

Initizar Ahmed Khan was first appointed on 27 Feb 2023 as Director at Dbact Pharma Private Limited.

The current boards of Initizar Ahmed Khan's companies include Aftab Ahmad Khan (Dbact Pharma Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available